MENU

Rese-cel Phase 1/2 Data: Cabaletta Bio’s Autoimmune Results 2026

The Manila Times USA
Overview
Cabaletta Bio reported Phase 1/2 data for rese-cel, showing durable, immunomodulator-free responses across dermatomyositis, lupus nephritis, and systemic sclerosis. The therapy demonstrated a favorable benefit-risk profile in 71 patients, suggesting a potential “immune reset” for severe autoimmune diseases.
In Depth

Key Clinical Findings

Cabaletta Bio presented Phase 1/2 data for resecabtagene autoleucel (rese-cel) showing high rates of immunomodulator-free durability. In dermatomyositis patients, 100% (6 of 6) maintained moderate-to-major Total Improvement Score (TIS) responses through one year, with 83% achieving this by Week 16. For lupus nephritis, 100% (5 of 5) of patients with follow-up between six months and two years achieved DORIS remission and showed histologic response or remission via repeat kidney biopsies.

In systemic sclerosis, 71% (5 of 7) of patients achieved rCRISS-50 and 86% (6 of 7) achieved rCRISS-25 at one year. Additionally, five patients with interstitial lung disease showed a 9% mean improvement in forced vital capacity (FVC) at the one-year mark.

Technical Details and Safety Profile

Rese-cel is an investigational chimeric antigen receptor (CAR) T cell therapy administered as a single, weight-based intravenous infusion following preconditioning and the discontinuation of immunomodulators. Clinical experience across 71 patients spanning myositis, systemic sclerosis, lupus, and myasthenia gravis indicates a favorable benefit-risk profile:

  • Cytokine Release Syndrome (CRS): 94% (67/71) experienced no or Grade 1 CRS; Grade 2 CRS occurred in 6% (4/71).
  • Neurotoxicity: 96% (68/71) experienced no immune effector cell-associated neurotoxicity syndrome (ICANS).
  • Other: No immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) was reported.

Background and Program Context

The data, with a cut-off date of September 4, 2026, are part of the REstoring SElf-Tolerance (RESET™) clinical development program. This program consists of single-arm, company-sponsored trials in dermatology, neurology, and rheumatology. The cohorts are designed to transition directly into registrational studies.

Significance and Outlook

The results suggest that a single dose of rese-cel can induce a durable immune reset, allowing patients to discontinue immunomodulators and reduce or eliminate steroid use. This is particularly significant for patients at risk of severe disability and end-organ damage who do not respond sufficiently to current therapies.

Source: https://www.manilatimes.net/2026/11/08/tmt-newswire/globenewswire/cabaletta-bio-presents-new-rese-cel-phase-12-clinical-data-at-acr-convergence-2026-featuring-immunomodulator-free-durability-and-favorable-benefit-risk-profile-across-autoimmune-diseases/2464767

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC